`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
`
`--------------------------------------------------------------X
`:
`
`MERCK SHARP & DOHME LLC,
`
`:
`
`Plaintiff,
`
`v.
`
`:
`:
`:
`:
`:
`:
`:
`:
`Defendant.
`---------------------------------------------------------------X
`
`C.A. No. 1:19-cv-00101-IMK
`
`MYLAN PHARMACEUTICALS INC.,
`
`STIPULATED MODIFIED AMENDED FINAL JUDGMENT
`
`THIS MATTER having come before the Court upon the Complaint of Plaintiff
`
`Merck Sharp & Dohme LLC (“Merck”) alleging that Defendant Mylan Pharmaceuticals Inc.
`
`(“Mylan”) infringed United States Patent No. 7,326,708 (“the ’708 Patent”) and United States
`
`Patent No. 8,414,921 (“the ’921 Patent”), and with Counterclaims filed by Mylan seeking a
`
`judgment of invalidity and noninfringement;
`
`WHEREAS following a bench trial before this Court, the Court, on September
`
`21, 2022, entered a Final Judgment (ECF No. 194) and amended on September 29, 2022 (ECF
`
`No. 197), in favor of Merck;
`
`WHEREAS subsequent to the entry of the Final Judgment, the parties have
`
`entered into a settlement agreement dated March 14, 2023 (the “Settlement Agreement”);
`
`WHEREAS the parties have jointly moved the Court to amend its Final
`
`Judgment pursuant to Federal Rule Civil Procedure 60(b), and for good cause shown by the
`
`parties, the Order is amended as follows:
`
`IT IS ORDERED that the Amended Final Judgment (ECF No. 197) is vacated;
`
`
`
`Case 1:19-cv-00101-TSK Document 209 Filed 05/02/23 Page 2 of 3 PageID #: 11993
`
`ORDERED AND ADJUDGED that Final Judgment shall be entered in favor of
`
`Plaintiff and against Defendant; and it is further
`
`ORDERED AND ADJUDGED that, pursuant to the provisions of 35 U.S.C. §
`
`271(e)(4)(B), Mylan, its officers, agents, servants, employees and attorneys, and those persons
`
`acting in privity or in active concert with Mylan, are enjoined, unless otherwise permitted
`
`pursuant to the terms of the Settlement Agreement, from engaging in the commercial
`
`manufacture, use, offer to sell, or sale within the United States, or importation into the United
`
`States (to the extent such activities are not protected by 35 U.S.C. § 271(e)(1)), of the drug
`
`products that are the subject of Mylan’s ANDA No. 202473 until the expiration of the ’708
`
`Patent; and it is further
`
`ORDERED AND ADJUDGED that, pursuant to the provisions of 35 U.S.C. §
`
`271(e)(4)(B), Mylan, its officers, agents, servants, employees and attorneys, and those persons
`
`acting in privity or in active concert with Mylan, are enjoined, unless otherwise permitted
`
`pursuant to the terms of the Settlement Agreement, from engaging in the commercial
`
`manufacture, use, offer to sell, or sale within the United States, or importation into the United
`
`States (to the extent such activities are not protected by 35 U.S.C. § 271(e)(1)), of the drug
`
`products that are the subject of Mylan’s ANDA No. 202478 until the expiration of the ’708
`
`Patent and the ’921 Patent; and it is further
`
`ORDERED that the stay of approval under 21 U.S.C. § 355(j)(5)(B)(iii) is
`
`terminated. Nothing herein prevents the U.S. Food and Drug Administration from granting final
`
`approval to ANDA Nos. 202473 and 202478 at any time.
`
`ORDERED AND ADJUDGED that the Clerk be and is hereby directed to enter
`
`forthwith this Amendment to the Order upon the Civil Docket.
`
`
`
`Case 1:19-cv-00101-TSK Document 209 Filed 05/02/23 Page 3 of 3 PageID #: 11994
`
`Dated: May 2, 2023
`
`UNITED STATES DISTRICT COURT JUDGE
`
`We hereby consent to the form and entry of this Order:
`
` /s/ Michael W. Carey
`Attorneys for Plaintiff
`Merck Sharp & Dohme LLC
`
` /s/ Gordon H. Copland
`Attorneys for Defendant
`Mylan Pharmaceuticals Inc.
`
`